Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase NA 1Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × OTHER × erdafitinib × Clear all
NCT03238196 2024-11-14

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 1 Completed
35 enrolled 19 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡